Scientech Research LLC Takes Position in Repligen Corporation $RGEN

Key Points

• Scientech Research LLC has made a new investment in Repligen Corporation, acquiring 14,437 shares valued at approximately $1,837,000, making it 18th in their investment portfolio.
• Repligen reported a revenue increase of 14.8% year-over-year, with quarterly earnings of $0.37 EPS, missing estimates by $0.03.
• Wall Street analysts have a consensus price target of $169.55 for Repligen, with ratings ranging from "buy" to "hold" among eight analysts.

Scientech Research LLC acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,437 shares of the biotechnology company's stock, valued at approximately $1,837,000. Repligen accounts for approximately 0.5% of Scientech Research LLC's holdings, making the stock its 18th biggest holding.

Other hedge funds have also bought and sold shares of the company. Alliancebernstein L.P. raised its position in shares of Repligen by 1.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock worth $130,317,000 after acquiring an additional 13,284 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Repligen during the first quarter worth approximately $262,000. Advisors Asset Management Inc. increased its holdings in Repligen by 3.5% in the first quarter. Advisors Asset Management Inc. now owns 11,138 shares of the biotechnology company's stock worth $1,417,000 after purchasing an additional 378 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in Repligen by 24.0% in the first quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company's stock valued at $58,561,000 after buying an additional 89,057 shares during the period. Finally, First Light Asset Management LLC boosted its holdings in shares of Repligen by 6.5% during the 1st quarter. First Light Asset Management LLC now owns 87,850 shares of the biotechnology company's stock worth $11,178,000 after buying an additional 5,395 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of several research analyst reports. Barclays assumed coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective for the company. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a report on Tuesday, July 22nd. Wells Fargo & Company cut their price objective on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $169.55.

Repligen Stock Up 1.3%

Shares of Repligen stock traded up $1.54 on Wednesday, hitting $120.23. The company had a trading volume of 986,487 shares, compared to its average volume of 775,657. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The stock has a 50 day moving average of $121.30 and a 200-day moving average of $128.72. The stock has a market capitalization of $6.76 billion, a price-to-earnings ratio of -480.90, a P/E/G ratio of 2.22 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.